Etravirine and rilpivirine resistance in HIV-1 subtype CRF01-AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens

Antiviral Therapy

Volumn 16, Issue 7, 2011, Pages 1113-1121

  Bunupuradah, Torsak ^a,b,c   Ananworanich, Jintanat ^a,b,c,d   Chetchotisakd, Ploenchan ^e   Kantipong, Pacharee ^f   Jirajariyavej, Supunnee ^g   Sirivichayakul, Sunee ^d   Munsakul, Warangkana ^h   Prasithsirikul, Wisit ⁱ   Sungkanuparph, Somnuek ^j   Bowonwattanuwong, Chureeratana ^k   Klinbuayaem, Virat ^l   Petoumenos, Kathy ^b   Hirschel, Bernard ^m   Bhakeecheep, Sorakij ⁿ   Ruxrungtham, Kiat ^a,c  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^e KHON KAEN UNIVERSITY   (Thailand)

^f Chiangrai Prachanukroh Hospital   (Thailand)

^g Taksin Hospital   (Thailand)

^h NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

ⁱ Bamrasnaradura Infectious Disease Institute   (Thailand)

^j MAHIDOL UNIVERSITY   (Thailand)

^k CHONBURI HOSPITAL   (Thailand)

^l Sanpatong Hospital   (Thailand)

^m UNIVERSITY OF GENEVA   (Switzerland)

ⁿ National Health Security Office   (Thailand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; ETRAVIRINE; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DRUG RESPONSE; DUET WEIGHTED SCORE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MONOGRAM WEIGHTED SCORE; MULTICENTER STUDY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; SCORING SYSTEM; THAILAND; TREATMENT FAILURE; VIRUS MUTATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MUTATION; NEVIRAPINE; NITRILES; PYRIDAZINES; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; STAVUDINE;

EID: 80055099715     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1906     Document Type: Article

References (37)

1. Beck EJ, Vitoria M, Mandalia S, Crowley S, Gilks CF, Souteyrand Y. National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines? AIDS 2006; 20:1497-1502.
2. Chetchotisakd P, Anunnatsiri S, Kiertiburanakul S, et al. High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant. J Int Assoc Physicians AIDS Care (Chic) 2006; 5:152-156.
3. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44:447-452. (Pubitemid 46147631)
4. Hammer SM, Eron JJ, Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
5. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1 2009. p 1-168. Department of Health and Human Services. (Accessed 8 June 2010.) Available from http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf
6. Bannister WP, Ruiz L, Cozzi-Lepri A, et al. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. AIDS 2008; 22:367-376.
7. Chaplin B, Eisen G, Idoko J, et al. Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy. AIDS Res Hum Retroviruses. 2011; 27:71-80.
8. Sirivichayakul S, Chantratita W, Sutthent R, Ruxrungtham K, Phanuphak P, Oelrichs RB. Survey of reverse transcriptase from the heterosexual epidemic of human immunodeficiency virus type 1 CRF01-AE in Thailand from 1990 to 2000. AIDS Res Hum Retroviruses 2001; 17:1077-1081. (Pubitemid 32881327)
9. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chantratita W. Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting. Curr HIV Res 2008; 6:474-476.
10. Kiertiburanakul S, Wiboonchutikul S, Sukasem C, Chantratita W, Sungkanuparph S. Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting. J Clin Virol 2010; 47:330-334.
11. Cohen C, Molina JM, Cahn P, et al. Pooled week 48 efficacy and safety results from ECHO and THRIVE, two doubleblind, randomised, Phase III trials comparing TMC278 versus efavirenz in treatment-naive, HIV-1-infected patients. XVIII International AIDS Conference. 18-23 July 2010, Vienna, Austria. Abstract THLBB206.
12. Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a nextgeneration nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010; 54:718-727.
13. Sungkanuparph S, Anekthananon T, Hiransuthikul N, et al. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. J Med Assoc Thai 2008; 91:1925-1935.
14. Lolekha R, Sirivichayakul S, Siangphoe U, et al. Resistance to dual nucleoside reverse-transcriptase inhibitors in children infected with HIV clade A/E. Clin Infect Dis 2005; 40:309-312. (Pubitemid 40110680)
15. Land S, Cunningham P, Zhou J, et al. TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. J Virol Methods 2009; 159:185-193.
16. Cotte L, Trabaud MA, Tardy JC, et al. Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms. J Med Virol 2009; 81:672-677.
17. Puthanakit T, Jourdain G, Hongsiriwon S, et al. HIV-1 drug resistance mutations in children after failure of firstline nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. HIV Med 2010; 11:565-572.
18. Benhamida J, Chappey C, Coakley E, Parkin NT. HIV-1 genotype algorithms for prediction of etravirine susceptibility: novel mutations and weighting factors identified through correlations to phenotype. Antivir Ther 2008; 13 Suppl 3:A142.
19. Haddad M, Stawiski E, Benhamida J, Coakley E. Improved genotypic algorithm for predicting etravirine susceptibility: comprehensive list of mutations identified through correlation with matched phenotype. 17th Conference on Retroviruses and Opportunistic Infection. 16-19 February 2010, San Francisco, CA, USA. Poster 574.
20. Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 2010; 24:503-514.
21. Vingerhoets J, Peeters M, Azijn H, et al. An update of the list of NNRTI mutations associated with decreased virological response to etravirine: multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data. Antivir Ther 2008; 13 Suppl 3:A26.
22. Rimsky LT, Azijn H, Tirry I, et al. In vitro resistance profile of TMC278, a next-generation NNRTI; evidence of a higher genetic barrier and a more robust resistance profile than first generation NNRTIs. XVIII International Drug Resistance Workshop. 9-13 June 2009, Fort Myers, FL, USA. Abstract 120.
23. Rimsky L, Eron J, Clotet B, et al. Characterization of the resistance profile of TMC278: 48-week analysis of the Phase 3 studies ECHO and THRIVE. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 12-15 September 2010, Boston, MA, USA. Abstract H-1810.
24. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med 2005; 37:360-363. (Pubitemid 40656185)
25. Taiwo B, Chaplin B, Penugonda S, et al. Suboptimal etravirine activity is common during failure of nevirapinebased combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1. Curr HIV Res 2010; 8:194-198.
26. Di Vincenzo P, Rusconi S, Adorni F, et al. Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA). HIV Med 2010; 11:530-534.
27. Marcelin AG, Flandre P, Descamps D, et al. Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients. Antimicrob Agents Chemother 2010; 54:72-77.
28. Di Giambenedetto S, Zazzi M, Corsi P, et al. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy. Antivir Ther 2009; 14:359-369.
29. Picchio G, Vingerhoets J, Tambuyzer L, Coakley E, Haddad M, Witek J. Prevalence of genotypic and phenotypic susceptibility to etravirine in US samples received for routine resistance testing. XVIII International AIDS Conference. 18-23 July 2010, Vienna, Austria. Poster MOPDB105.
30. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:29-38. (Pubitemid 47017466)
31. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV- 1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:39-48. (Pubitemid 47017467)
32. Peeters M, Vingerhoets J, Tambuyzer L, et al. Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials. AIDS 2010; 24:921-924.
33. Nozza S, Galli L, Visco F, et al. Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. AIDS 2010; 24:924-928.
34. Imaz A, del Saz SV, Ribas MA, et al. Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr 2009; 52:382-386.
35. Ruxrungtham K, Pedro RJ, Latiff GH, et al. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naive, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Med 2008; 9:883-896.
36. The TMC125-C223 Writing Group. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV- 1: primary 24-week analysis. AIDS 2007; 21:F1-F10.
37. Pozniak AL, Morales-Ramirez J, Katabira E, et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a Phase IIb randomized trial. AIDS 2010; 24:55-65.